Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
- PMID: 18695978
- DOI: 10.1007/s00216-008-2291-6
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation
Abstract
We investigated the elimination routes for the 200 drugs that are sold most often by prescription count in the United States. The majority (78%) of the hepatically cleared drugs were found to be subject to oxidative metabolism via cytochromes P450 of the families 1, 2 and 3, with major contributions from CYP3A4/5 (37% of drugs) followed by CYP2C9 (17%), CYP2D6 (15%), CYP2C19 (10%), CYP1A2 (9%), CYP2C8 (6%), and CYP2B6 (4%). Clinically well-established polymorphic CYPs (i.e., CYP2C9, CYP2C19, and CYP2D6) were involved in the metabolism of approximately half of those drugs, including (in particular) NSAIDs metabolized mainly by CYP2C9, proton-pump inhibitors metabolized by CYP2C19, and beta blockers and several antipsychotics and antidepressants metabolized by CYP2D6. In this review, we provide an up-to-date summary of the functional polymorphisms and aspects of the functional genomics of the major human drug-metabolizing cytochrome P450s, as well as their clinical significance.
Similar articles
-
Cytochrome P450 in Pharmacogenetics: An Update.Adv Pharmacol. 2018;83:3-32. doi: 10.1016/bs.apha.2018.04.007. Adv Pharmacol. 2018. PMID: 29801580 Review.
-
Cytochrome P450 pharmacogenetics and cancer.Oncogene. 2006 Mar 13;25(11):1679-91. doi: 10.1038/sj.onc.1209377. Oncogene. 2006. PMID: 16550168 Review.
-
Bench to bedside: Pharmacogenomics, adverse drug interactions, and the cytochrome P450 system.Acad Emerg Med. 2005 Dec;12(12):1227-35. doi: 10.1197/j.aem.2005.06.027. Epub 2005 Nov 10. Acad Emerg Med. 2005. PMID: 16282513 Review.
-
Pharmacogenomic protocols in CNS disorders and dementia.Neurodegener Dis. 2010;7(1-3):167-9. doi: 10.1159/000289230. Epub 2010 Mar 3. Neurodegener Dis. 2010. PMID: 20197699
-
Pharmacogenetics-guided dose modifications of antidepressants.Clin Lab Med. 2008 Dec;28(4):619-26. doi: 10.1016/j.cll.2008.05.006. Clin Lab Med. 2008. PMID: 19059066 Review.
Cited by
-
Atorvastatin-related rhabdomyolysis and acute renal failure in a genetically predisposed patient with potential drug-drug interaction.Int J Clin Pharm. 2012 Dec;34(6):825-7. doi: 10.1007/s11096-012-9717-0. Epub 2012 Oct 18. Int J Clin Pharm. 2012. PMID: 23076661
-
Extrahepatic cytochrome P450 epoxygenases: pathophysiology and clinical significance in human gastrointestinal cancers.Oncotarget. 2021 Feb 16;12(4):379-391. doi: 10.18632/oncotarget.27893. eCollection 2021 Feb 16. Oncotarget. 2021. PMID: 33659048 Free PMC article. Review.
-
Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.Pharmacogenomics. 2009 Sep;10(9):1423-31. doi: 10.2217/pgs.09.72. Pharmacogenomics. 2009. PMID: 19761366 Free PMC article.
-
Correlating structure and function of drug-metabolizing enzymes: progress and ongoing challenges.Drug Metab Dispos. 2014 Jan;42(1):9-22. doi: 10.1124/dmd.113.054627. Epub 2013 Oct 15. Drug Metab Dispos. 2014. PMID: 24130370 Free PMC article. Review.
-
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity.Front Pharmacol. 2022 Jun 16;13:912618. doi: 10.3389/fphar.2022.912618. eCollection 2022. Front Pharmacol. 2022. PMID: 35784699 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
